|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Agendia BV, of Amsterdam, the Netherlands, presented data showing its ColoPrint product can predict the risk of relapse and recurrence in Stage II colon cancer patients. The technology is based on microarray gene expression profiles.
o Aldagen Inc., of Durham, N.C., added three new sites for its 20-patient trial with ALD-301 for the treatment of critical limb ischemia: Duke University Medical Center, also in Durham; Indiana University, in Indianapolis; and St. Joseph's Research Institute, in Atlanta. The sites join Texas Heart Institute at St. Luke's Episcopal Hospital in Houston. ALD-301 is described as a potent population of stem and progenitor cells isolated ...